Trial Profile
A Two-part, Phase I, Open-label, Multicenter, Two-period, One-sequence Study to Investigate the Effect of Itraconazole and Rifampin on the PK of Vemurafenib at Steady State
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Itraconazole (Primary) ; Rifampicin (Primary) ; Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Pharmacokinetics
- Sponsors Genentech
- 23 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Jun 2018 Planned End Date changed from 29 Nov 2018 to 8 Jan 2019.